Information de reference pour ce titreAccession Number: | 00000605-201312170-00007.
|
Author: | Meijer, C. Arnoud MD; Stijnen, Theo PhD; Wasser, Martin N.J.M. MD, PhD; Hamming, Jaap F. MD, PhD; van Bockel, J. Hajo MD, PhD; Lindeman, Jan H.N. MD, PhD; for the Pharmaceutical Aneurysm Stabilisation Trial Study Group *
|
Institution: | From Leiden University Medical Center, Leiden, the Netherlands.
|
Title: | |
Source: | Annals of Internal Medicine. 159(12):815-823, December 17, 2013.
|
Abstract: | Background: Doxycycline inhibits formation and progression of abdominal aortic aneurysms (AAAs) in preclinical models of the disease, but it is unclear whether and how this observation translates to humans.
Objective: To test whether doxycycline inhibits AAA progression in humans.
Design: Randomized, placebo-controlled, double-blind trial. (Dutch Trial Registry: NTR 1345)
Setting: 14 Dutch hospitals.
Patients: 286 patients with small AAAs between October 2008 and June 2011.
Intervention: Daily dose of 100 mg of doxycycline (n = 144) or placebo (n = 142) for 18 months.
Measurements: The primary outcome measure was aneurysm growth at 18 months, as estimated by repeated single-observer ultrasonography. Secondary outcomes included growth at 6 and 12 months and the need for elective surgery.
Results: Mean aneurysm diameter (approximately 43 mm) and other baseline characteristics were similar in both groups. Doxycycline treatment was associated with increased aneurysm growth (4.1 mm in the doxycycline group vs. 3.3 mm in the placebo group at 18 months; difference, 0.8 mm [95% CI, 0.1 to 1.4 mm]; P = 0.016 mm). Twenty-one patients receiving doxycycline and 22 patients receiving placebo had elective surgical repair (Kaplan-Meier estimates were 16.1% for those receiving doxycycline and 16.5% for those receiving placebo; difference, -0.4% [CI, -9.3% to 8.5%]; P = 0.83). Time to repair was similar in the groups (P = 0.92).
Limitations: This study focuses on patients with small AAAs. As such, whether the data can be extrapolated to larger AAAs (>55 mm) is unclear. The high number of elective repairs (n = 43) was unanticipated. Moreover, the study did not follow patients who withdrew because of an adverse effect.
Conclusion: This trial found that 18 months of doxycycline therapy did not reduce aneurysm growth and did not influence the need for AAA repair or time to repair.
Primary Funding Source: The Netherlands Organisation for Health Research and Development, and the NutsOhra Fund.
(C) 2013 American College of Physicians
|
References: | 1. Brown LC, Powell JT. Risk factors for aneurysm rupture in patients kept under ultrasound surveillance. UK Small Aneurysm Trial Participants. Ann Surg. 1999;230:289-96. [PMID: 10493476]
2. Moll FL, Powell JT, Fraedrich G, Verzini F, Haulon S, Waltham M, et al; European Society for Vascular Surgery. Management of abdominal aortic aneurysms clinical practice guidelines of the European society for vascular surgery. Eur J Vasc Endovasc Surg. 2011;41 Suppl 1:S1-S58. [PMID: 21215940]
3. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. The UK Small Aneurysm Trial Participants. Lancet. 1998;352:1649-55. [PMID: 9853436]
4. Lederle FA, Wilson SE, Johnson GR, Reinke DB, Littooy FN, Acher CW, et al; Aneurysm Detection and Management Veterans Affairs Cooperative Study Group. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med. 2002;346:1437-44. [PMID: 12000813]
5. Cao P; CAESAR Trial Collaborators. Comparison of surveillance vs Aortic Endografting for Small Aneurysm Repair (CAESAR) trial: study design and progress. Eur J Vasc Endovasc Surg. 2005;30:245-51. [PMID: 16130206]
6. Ouriel K. The PIVOTAL study: a randomized comparison of endovascular repair versus surveillance in patients with smaller abdominal aortic aneurysms. J Vasc Surg. 2009;49:266-9. [PMID: 19174266]
7. Powell JT, Greenhalgh RM. Clinical practice. Small abdominal aortic aneurysms. N Engl J Med. 2003;348:1895-901. [PMID: 12736283]
8. Baxter BT, Terrin MC, Dalman RL. Medical management of small abdominal aortic aneurysms. Circulation. 2008;117:1883-9. [PMID: 18391122]
9. Bergqvist D. Pharmacological interventions to attenuate the expansion of abdominal aortic aneurysm (AAA)-a systematic review. Eur J Vasc Endovasc Surg. 2011;41:663-7. [PMID: 21330159]
10. Freestone T, Turner RJ, Coady A, Higman DJ, Greenhalgh RM, Powell JT. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 1995;15:1145-51. [PMID: 7627708]
11. Thompson RW, Parks WC. Role of matrix metalloproteinases in abdominal aortic aneurysms. Ann N Y Acad Sci. 1996;800:157-74. [PMID: 8958991]
12. Thompson RW, Geraghty PJ, Lee JK. Abdominal aortic aneurysms: basic mechanisms and clinical implications. Curr Probl Surg. 2002;39:110-230. [PMID: 11884965]
13. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54:258-65. [PMID: 16443056]
14. Monk E, Shalita A, Siegel DM. Clinical applications of non-antimicrobial tetracyclines in dermatology. Pharmacol Res. 2011;63:130-45. [PMID: 20937386]
15. Dodd BR, Spence RA. Doxycycline inhibition of abdominal aortic aneurysm growth: a systematic review of the literature. Curr Vasc Pharmacol. 2011;9:471-8. [PMID: 21595625]
16. Mosorin M, Juvonen J, Biancari F, Satta J, Surcel HM, Leinonen M, et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg. 2001;34:606-10. [PMID: 11668312]
17. Baxter BT, Pearce WH, Waltke EA, Littooy FN, Hallett JW Jr, Kent KC, et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (phase II) multicenter study. J Vasc Surg. 2002;36:1-12. [PMID: 12096249]
18. Scott NW, McPherson GC, Ramsay CR, Campbell MK. The method of minimization for allocation to clinical trials. a review. Control Clin Trials. 2002;23:662-74. [PMID: 12505244]
19. Lindeman JH, Abdul-Hussien H, van Bockel JH, Wolterbeek R, Kleemann R. Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation. 2009;119:2209-16. [PMID: 19364980]
20. Akkersdijk GJ, Puylaert JB, Coerkamp EG, de Vries AC. Accuracy of ultrasonographic measurement of infrarenal abdominal aortic aneurysm. Br J Surg. 1994;81:376. [PMID: 8173903]
21. Hartshorne TC, McCollum CN, Earnshaw JJ, Morris J, Nasim A. Ultrasound measurement of aortic diameter in a national screening programme. Eur J Vasc Endovasc Surg. 2011;42:195-9. [PMID: 21439859]
22. Beales L, Wolstenhulme S, Evans JA, West R, Scott DJ. Reproducibility of ultrasound measurement of the abdominal aorta. Br J Surg. 2011;98:1517-25. [PMID: 21861264]
23. Kauffmann C, Tang A, Therasse E, Giroux MF, Elkouri S, Melanson P, et al. Measurements and detection of abdominal aortic aneurysm growth: accuracy and reproducibility of a segmentation software. Eur J Radiol. 2012;81:1688-94. [PMID: 21601403]
24. Brady AR, Thompson SG, Fowkes FG, Greenhalgh RM, Powell JT; UK Small Aneurysm Trial Participants. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation. 2004;110:16-21. [PMID: 15210603]
25. Powell JT, Sweeting MJ, Brown LC, Gotensparre SM, Fowkes FG, Thompson SG. Systematic review and meta-analysis of growth rates of small abdominal aortic aneurysms. Br J Surg. 2011;98:609-18. [PMID: 21412998]
26. Fitzmaurice GM, Ravichandran C. A primer in longitudinal data analysis. Circulation. 2008;118:2005-10. [PMID: 18981315]
27. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. 2nd ed. Hoboken, NJ: J Wiley; 2011.
28. Rizopoulos D. Joint Models for Longitudinal and Time-to-Event Data: With Applications in R. Boca Raton, FL: CRC Pr; 2012.
29. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. 2nd ed. New York, NY: Springer-Verlag; 2009.
30. Panel on Handling Missing Data in Clinical Trials, National Research Council. The Prevention and Treatment of Missing Data in Clinical Trials. Washington, DC: National Academies Pr; 2010.
31. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-10. [PMID: 2868172]
32. Doxycycline and (photo-)onycholysis. Accessed at www.lareb.nl/LarebCorporateWebsite/media/publicaties/kwb_2003_1_doxyc.pdf on 10 January 2012.
33. Doxycycline and smell and taste disorders. Accessed at www.lareb.nl/LarebCorporateWebsite/media/publicaties/kwb_2009_4_doxyc.pdf on 10 January 2012.
34. Aziz F, Kuivaniemi H. Role of matrix metalloproteinase inhibitors in preventing abdominal aortic aneurysm. Ann Vasc Surg. 2007;21:392-401. [PMID: 17484978]
35. Trollope A, Moxon JV, Moran CS, Golledge J. Animal models of abdominal aortic aneurysm and their role in furthering management of human disease. Cardiovasc Pathol. 2011;20:114-23. [PMID: 20133168]
36. Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC, Thompson RW. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg. 1996;23:336-46. [PMID: 8637112]
37. Curci JA, Petrinec D, Liao S, Golub LM, Thompson RW. Pharmacologic suppression of experimental abdominal aortic aneurysms: a comparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg. 1998;28:1082-93. [PMID: 9845660]
38. Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2003;23:483-8. [PMID: 12615694]
39. Bartoli MA, Parodi FE, Chu J, Pagano MB, Mao D, Baxter BT, et al. Localized administration of doxycycline suppresses aortic dilatation in an experimental mouse model of abdominal aortic aneurysm. Ann Vasc Surg. 2006;20:228-36. [PMID: 16572291]
40. Turner GH, Olzinski AR, Bernard RE, Aravindhan K, Karr HW, Mirabile RC, et al. In vivo serial assessment of aortic aneurysm formation in apolipoprotein E-deficient mice via MRI. Circ Cardiovasc Imaging. 2008;1:220-6. [PMID: 19808546]
41. Kloppenburg M, Brinkman BM, de Rooij-Dijk HH, Miltenburg AM, Daha MR, Breedveld FC, et al. The tetracycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes. Antimicrob Agents Chemother. 1996;40:934-40. [PMID: 8849255]
42. O'Brien J, Lyons T, Monks J, Lucia MS, Wilson RS, Hines L, et al. Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species. Am J Pathol. 2010;176:1241-55. [PMID: 20110414]
43. Manning BJ, Kristmundsson T, Sonesson B, Resch T. Abdominal aortic aneurysm diameter: a comparison of ultrasound measurements with those from standard and three-dimensional computed tomography reconstruction. J Vasc Surg. 2009;50:263-8. [PMID: 19631858]
44. Propanolol Aneurysm Trial Investigators. Propranolol for small abdominal aortic aneurysms: results of a randomized trial. J Vasc Surg. 2002;35:72-9. [PMID: 11802135]
45. Rizopoulos D. JM: An R package for the joint modelling of longitudinal and time-to-event data. J Stat Softw. 2010;35:1-33.
46. Rizopoulos D. Fast fitting of joint models for longitudinal and event time data using a pseudo-adaptive Gaussian quadrature rule. Comput Stat Data Anal. 2012;56:491-501.
47. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18:681-94. [PMID: 10204197]
48. Rubin DB. Multiple Imputation for Nonresponse in Surveys. Hoboken, NJ: J Wiley; 1987.
|
Language: | English.
|
Document Type: | Original Research.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0003-4819
|
NLM Journal Code: | 0372351, 5a6
|
Annotation(s) | |
|
|